Galapagos ends inflammation partnership with Janssen

Published: 18-Mar-2015
Research & Development Pharmaceutical

Long-running alliance started in 2007


Galapagos, a biotechnology company with operations in Belgium and the Netherlands, is to terminate its long-running inflammation alliance with Belgian firm Janssen Pharmaceutica.

No reasons was given for the ending of the eight-year alliance and Galapagos said it viewed the molecules emerging from the alliance as strong additions to its growing pipeline.

The company now owns all rights to candidate drug GLPG1690, a selective autotaxin inhibitor.

Galapagos said a First-in-Human Phase I trial for the experimental drug has been successfully completed and it is preparing a Phase II clinical trial in idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal lung disease, to be filed for approval before the end of this year.

Piet Wigerinck, Chief Scientific Officer of Galapagos, said: 'The alliance with Janssen has been underway since October 2007 and has generated three clinical molecules, two of which are now proprietary Phase II assets of Galapagos: GLPG1205 and GLPG1690.

'This programme is a valuable component of our development portfolio, and regaining the rights is a next step in our transformation into a mature biotech company with a proprietary product pipeline.'

  • Companies:
  • Galapagos NV
  • Johnson and Johnson
See more

You may also like

Regulatory

Johnson & Johnson submits nipocalimab application to the FDA following positive Phase III results

Read more
The drug — in combination with the standard of care regimen — was able to exhibit sustained disease control over the 24 week trial period

Trending Articles

  1. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  2. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  3. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  4. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  5. How flow chemistry is transforming drug discovery New Syrris eBook explores techniques driving efficiency and innovation

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Regulatory

Johnson & Johnson submits nipocalimab application to the FDA following positive Phase III results

The drug — in combination with the standard of care regimen — was able to exhibit sustained disease control over the 24 week trial period
Regulatory

Johnson & Johnson's Rybrevant-Lazcluze combo receives FDA approval for EGFR-mutated lung cancer

The combination therapy was seen to reduce risk of disease progression or death by 30% compared to the current standard of care, osimertinib
Regulatory

Johnson & Johnson seeks approval for subcutaneous formulation of Rybrevant to treat EGFR-mutated NSCLC

The submission to the EMA is supported by data from the Phase III PALOMA-3 study, which showed the non-inferiority of subcutaneous Rybrevant to intravenous administration
Research & Development

Johnson & Johnson's TAR-200 monotherapy exhibits >80% CR rate in bladder cancer

TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (BCG-HR-NMIBC)
Marketing

Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation

The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Regulatory

FDA grants approval for Johnson & Johnson's antibody for treatment of myeloma

Johnson & Johnson have received accelerated approval of TALVEY, a first-in-class bispecific antibody. TALVEY is a bispecific T-cell engaging antibody that binds to the CD3 receptor
Drug Delivery

Galapagos and NovAliX enter integrated drug discovery collaboration

The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Subscribe now